A Phase 1/2, Open Label, Dose Escalation Study of Intravenous Administration of Single Agent NEOD001 in Subjects With Light Chain (AL) Amyloidosis

Trial Profile

A Phase 1/2, Open Label, Dose Escalation Study of Intravenous Administration of Single Agent NEOD001 in Subjects With Light Chain (AL) Amyloidosis

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 03 Nov 2017

At a glance

  • Drugs NEOD 001 (Primary)
  • Indications Amyloidosis
  • Focus Adverse reactions
  • Sponsors Onclave Therapeutics; Prothena
  • Most Recent Events

    • 25 Jun 2017 Results presented at the 22nd Congress of the European Haematology Association.
    • 28 Apr 2017 Results from the expansion phase (n=42), presented at the 69th Annual Meeting of the American Academy of Neurology.
    • 06 Dec 2016 Results assessing association between organ response and depth and time since last plasma cell-directed treatment, presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top